Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Menopause. 2011 Mar;18(3):279-84. doi: 10.1097/gme.0b013e3181f2ea2e.
We sought to obtain preliminary data regarding the efficacy of omega-3 fatty acids for major depressive disorder associated with the menopausal transition. Secondary outcomes were assessed for vasomotor symptoms (or hot flashes).
After a single-blind placebo lead-in, participants received 8 weeks of treatment with open-label omega-3 fatty acid capsules (eicosapentaenoic acid and docosahexaenoic acid, 2 g/d). The Montgomery-Asberg Depression Rating Scale (MADRS) was the primary outcome measure. Hot flashes were monitored prospectively using daily diaries and the Hot Flash Related Daily Interference Scale. Blood samples for plasma pretreatment and posttreatment essential fatty acid assays were obtained. Because of the small sample size, data were analyzed using nonparametric techniques.
Of 20 participants treated with omega-3 fatty acids, 19 (95%) completed the study. None discontinued because of adverse effects. The pretreatment and final mean MADRS scores were 24.2 and 10.7, respectively, reflecting a significant decrease in MADRS scores (P < 0.0001). The response rate was 70% (MADRS score decrease of ≥50%), and the remission rate was 45% (final MADRS score of ≤). Responders had significantly lower pretreatment docosahexaenoic acid levels than nonresponders did (P = 0.03). Hot flashes were present in 15 (75%) participants. Among those with hot flashes at baseline, the number of hot flashes per day improved significantly from baseline (P = 0.02) and Hot Flash Related Daily Interference Scale scores decreased significantly (P = 0.006).
These data support further study of omega-3 fatty acids for major depressive disorder and hot flashes in women during the menopausal transition.
我们旨在获得关于ω-3 脂肪酸治疗与更年期过渡相关的重度抑郁症的疗效的初步数据。次要结果评估血管舒缩症状（或热潮红）。
在单盲安慰剂导入期后，参与者接受了 8 周的 ω-3 脂肪酸胶囊（二十碳五烯酸和二十二碳六烯酸，2 克/天）开放标签治疗。主要结局测量是蒙哥马利-阿斯伯格抑郁评定量表（MADRS）。使用每日日记和热潮红相关日常干扰量表前瞻性监测热潮红。获得用于血浆预处理和治疗后必需脂肪酸测定的血液样本。由于样本量小，使用非参数技术分析数据。
在接受 ω-3 脂肪酸治疗的 20 名参与者中，有 19 名（95%）完成了研究。没有因为不良反应而停药的。预处理和最终平均 MADRS 评分分别为 24.2 和 10.7，表明 MADRS 评分显著降低（P < 0.0001）。应答率为 70%（MADRS 评分下降≥50%），缓解率为 45%（最终 MADRS 评分≤）。应答者的预处理二十二碳六烯酸水平明显低于无应答者（P = 0.03）。15 名（75%）参与者存在热潮红。在基线时有热潮红的参与者中，每日热潮红的数量从基线显著改善（P = 0.02），热潮红相关日常干扰量表评分显著降低（P = 0.006）。
这些数据支持进一步研究 ω-3 脂肪酸治疗更年期过渡期间女性的重度抑郁症和热潮红。
